Luckily, all these vaccines look like they're protecting us from severe disease, said Dr. Monica Gandhi of the University of California, San Francisco, citing study results for five vaccines used around the world and a sixth that's still in review.
And real-world evidence as millions of people receive the vaccines show they're all working very well.
Still, people might wonder if one is better than another since studies conducted before the vaccines were rolled out found varying levels of effectiveness. The problem is they don't offer apples-to-apples comparisons.
Consider the two-dose vaccines from Pfizer and Moderna, found to be about 95 per cent effective at preventing illness. Studies for those shots counted a COVID-19 case whether it was mild, moderate or severe and were conducted before worrisome mutated versions of the virus began circulating.
Then Johnson & Johnson tested a single-dose vaccine and didn't count mild illnesses. J&J's shot was 66 per cent protective against moderate to severe illness in a large international study. In just the US, where there's less spread of variants, it was 72 per cent effective. More importantly, once the vaccine's effect kicked in it prevented hospitalisation and death.
AstraZeneca's two-dose vaccine used in many countries has faced questions about the exact degree of its effectiveness indicated by studies. But experts agree those shots, too, protect against the worst outcomes.
Around the world, hospitalizations are dropping in countries where vaccines have been rolling out including Israel, England and Scotland regardless of which shots are given. And the US government's first look at real-world data among essential workers provided further evidence that the Pfizer and Moderna vaccines are highly protective -- 90 per cent -- against infections whether there were symptoms or not.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.